TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) has provided an update.
BerGenBio ASA announced its financial results for the first half of 2025 and significant strategic changes, including the closure of its lead clinical study and a merger with Oncoinvent ASA. This merger, approved by an Extraordinary General Meeting, aims to combine resources and expertise to advance radiopharmaceutical cancer therapies, marking a new phase for the company and its shareholders.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA is a biotechnology company focused on developing innovative cancer therapies. The company has been involved in clinical studies for treatments in non-small cell lung cancer and has recently shifted its focus towards radiopharmaceutical cancer therapies through a merger with Oncoinvent ASA.
Average Trading Volume: 328,259
Current Market Cap: NOK46.67M
For detailed information about BRRGF stock, go to TipRanks’ Stock Analysis page.